Literature DB >> 20657274

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) improves the innate immune response and enhances survival in murine polymicrobial sepsis.

Katharina Cziupka1, Alexandra Busemann, Lars Ivo Partecke, Christian Pötschke, Matthias Rath, Tobias Traeger, Pia Koerner, Wolfram von Bernstorff, Wolfram Kessler, Stephan Diedrich, Frank Ulrich Weiss, Stefan Maier, Barbara M Bröker, Claus-Dieter Heidecke.   

Abstract

OBJECTIVE: To investigate the role of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in postoperative polymicrobial abdominal sepsis.Sepsis is the leading cause of death among critically ill surgical patients. TRAIL is commonly known as an apoptosis-inducing agent in cancer cells. It also plays an important role in the regulation of inflammatory reactions. The role of TRAIL in polymicrobial sepsis is still unclear.
DESIGN: Experimental animal model.
SETTING: University laboratory.
SUBJECTS: C57BL/6 mice.
INTERVENTIONS: Colon ascendens stent peritonitis (CASP) was induced in female mice. One hour, 24 hrs, and 48 hrs after induction of CASP, murine recombinant TRAIL was given intravenously.
MEASUREMENTS AND MAIN RESULTS: This study demonstrates a protective effect of TRAIL in CASP, an experimental model of murine polymicrobial sepsis. Intravenous administration of recombinant TRAIL to mice after CASP induction led to highly significantly prolonged survival. The migration of effector cells into the peritoneal cavity was strongly enhanced. Consequently, TRAIL-treated mice eliminated bacteria significantly better from the peritoneal cavity, the source of infection. Systemic spread of gut bacteria was also reduced by several orders of magnitude. As a result of the reduced systemic spread of bacteria, the accumulation of neutrophils within the spleen and mesenteric lymph nodes was strongly decreased.
CONCLUSION: TRAIL-treated mice are highly protected from abdominal sepsis. Because diagnosis and therapy are frequently delayed in human sepsis, it is remarkable that TRAIL is effective when given via a therapeutic approach. Therefore, this study suggests a therapeutic potential for TRAIL in human sepsis. This should be addressed in future trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20657274     DOI: 10.1097/CCM.0b013e3181eedaa8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  18 in total

Review 1.  [Pathophysiology of peritonitis].

Authors:  K Beyer; P Menges; W Keßler; C-D Heidecke
Journal:  Chirurg       Date:  2016-01       Impact factor: 0.955

2.  RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages.

Authors:  Zhenyu Yao; Peng Zhang; Hui Guo; Juan Shi; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  Mol Oncol       Date:  2014-12-30       Impact factor: 6.603

3.  When host defense goes awry: Modeling sepsis-induced immunosuppression.

Authors:  Scott B Hu; Alexander Zider; Jane C Deng
Journal:  Drug Discov Today Dis Models       Date:  2012

4.  Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis.

Authors:  Edward J Schenck; Kevin C Ma; David R Price; Thomas Nicholson; Clara Oromendia; Eliza Rose Gentzler; Elizabeth Sanchez; Rebecca M Baron; Laura E Fredenburgh; Jin-Won Huh; Ilias I Siempos; Augustine Mk Choi
Journal:  JCI Insight       Date:  2019-05-02

5.  IL-37 Causes Excessive Inflammation and Tissue Damage in Murine Pneumococcal Pneumonia.

Authors:  Anja E Schauer; Tilman E Klassert; Carolin von Lachner; Diana Riebold; Anne Schneeweiß; Magdalena Stock; Mario M Müller; Sven Hammerschmidt; Philip Bufler; Ulrike Seifert; Kristina Dietert; Charles A Dinarello; Marcel F Nold; Achim D Gruber; Claudia A Nold-Petry; Hortense Slevogt
Journal:  J Innate Immun       Date:  2017-06-10       Impact factor: 7.349

6.  Dynamic changes in human single-cell transcriptional signatures during fatal sepsis.

Authors:  Xinru Qiu; Jiang Li; Jeff Bonenfant; Lukasz Jaroszewski; Aarti Mittal; Walter Klein; Adam Godzik; Meera G Nair
Journal:  J Leukoc Biol       Date:  2021-09-24       Impact factor: 4.962

7.  Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.

Authors:  Piya Chaemsaithong; Roberto Romero; Steven J Korzeniewski; Alyse G Schwartz; Tamara Stampalija; Zhong Dong; Lami Yeo; Edgar Hernandez-Andrade; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2013-04-22

8.  Maternal plasma soluble TRAIL is decreased in preeclampsia.

Authors:  Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Tamara Stampalija; Nandor Gabor Than; Zhong Dong; Jezid Miranda; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-13

9.  TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.

Authors:  Kathrin Steinwede; Stefanie Henken; Jennifer Bohling; Regina Maus; Bianca Ueberberg; Christina Brumshagen; Erik L Brincks; Thomas S Griffith; Tobias Welte; Ulrich A Maus
Journal:  J Exp Med       Date:  2012-10-15       Impact factor: 14.307

10.  Efficacy and safety of active negative pressure peritoneal therapy for reducing the systemic inflammatory response after damage control laparotomy (the Intra-peritoneal Vacuum Trial): study protocol for a randomized controlled trial.

Authors:  Derek J Roberts; Craig N Jenne; Chad G Ball; Corina Tiruta; Caroline Léger; Zhengwen Xiao; Peter D Faris; Paul B McBeth; Christopher J Doig; Christine R Skinner; Stacy G Ruddell; Paul Kubes; Andrew W Kirkpatrick
Journal:  Trials       Date:  2013-05-16       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.